{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:05:34Z","timestamp":1794366334556,"version":"4.9.0"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,3,10]],"date-time":"2010-03-10T00:00:00Z","timestamp":1268179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:p><jats:bold>Background and Objectives\u2002<\/jats:bold> Most cell therapy products (CTP) are infused or processed shortly after collection but in some cases this may be delayed for up to 48\u2003h. A number of variables such as temperature and cell concentration are of critical importance for the integrity of CTP during this time.<\/jats:p><jats:p><jats:bold>Materials and Methods\u2002<\/jats:bold> We conducted a survey of cellular therapy laboratories to ascertain current practices for CTP transportation.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> There were 194 respondents of whom 90% shipped or received CTP \u2013 84% allogeneic, 71% autologous and 62% therapeutic cells. Processing facilities shipped or received the following products \u2013 hematopoietic progenitor cells (HPC), Marrow 73%; HPC, Apheresis 90%; HPC, Cord Blood 54% and others 14%. Other CTP included donor lymphocytes, mesenchymal stem cells (MSC), natural killer cells, buffy coat neutrophils and virus\u2010specific cytotoxic T lymphocytes (CTL). More than 70% of respondents believed that it was acceptable for CTP to be held for up to 2\u2003h without checking the temperature or cell density and a similar proportion agreed that putting products in containers to control parameters such as temperature within this time period was unnecessary. The majority of centres shipped or received between 1 and 10 CTP annually and 66% received products taking more than 2\u2003h to ship. Of these, 82% specified the conditions for temperature in transit whilst 57% monitored temperature in transit and 74% of these used a data logger. The temperature range most commonly specified was 18\u201324\u00b0C. The majority of processing facilities did not request an adjustment to the cell density even for products taking more than 2\u2003h to reach their facility. More than 90% of respondents tested HPC for CD34<jats:sup>+<\/jats:sup> cells, viability and sterility; 40\u201348% performed colony\u2010forming unit\u2013granulocyte macrophage (CFU\u2013GM) analysis. Only viability was thought by &gt;\u200350% of respondents to be impacted by temperature, cell density and other parameters.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> Understanding current practice will help in the design of future studies for CTP storage and transportation.<\/jats:p>","DOI":"10.1111\/j.1423-0410.2010.01329.x","type":"journal-article","created":{"date-parts":[[2010,3,10]],"date-time":"2010-03-10T05:55:16Z","timestamp":1268200516000},"page":"168-173","source":"Crossref","is-referenced-by-count":21,"title":["Transportation of cellular therapy products: report of a survey by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) collaborative"],"prefix":"10.1111","volume":"99","author":[{"given":"D. H.","family":"Pamphilon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Selogie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. M.","family":"Szczepiorkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the BEST Collaborative Cellular Therapies team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702175"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1996.5.681"},{"key":"e_1_2_6_4_2","first-page":"599","volume-title":"Thomas\u2019 Haematopoietic Cell Transplantation","author":"Rowley SD","year":"2004"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920070307"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705420"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/14653240600620994"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199805150-00024"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.9.2731.2731"},{"key":"e_1_2_6_10_2","first-page":"130A","article-title":"Quality indicators of unrelated allogenic harvests in the Ottawa region transplant program","volume":"48","author":"Halpenny M","year":"2008","journal-title":"Transfusion"},{"key":"e_1_2_6_11_2","unstructured":"Directive 2004\/23\/EC of the European Parliament and Council on setting standards of quality and safety for the donation procurement testing processing preservation storage and distribution of human tissues and cells.http:\/\/www.transfusionguidelines.org.uk"},{"key":"e_1_2_6_12_2","unstructured":"Commission Directive 2006\/17\/EC implementing Directive 2004\/23\/EC of the European Parliament and Council as regards certain technical requirements for the donation procurement and testing of human tissues and cells.http:\/\/www.transfusionguidelines.org.uk"},{"key":"e_1_2_6_13_2","unstructured":"Commission Directive 2006\/86\/EC implementing Directive 2004\/23\/EC of the European Parliament and Council as regards traceability requirements notification of severe adverse reactions and events and certain technical requirements for the coding processing preservation storage and distribution of human tissues and cells.http:\/\/www.transfusionguidelines.org.uk"},{"key":"e_1_2_6_14_2","unstructured":"Standards for Haematopoietic Progenitor Cell Collection Processing and Transplantation. Fourth Edition (2008) from the Foundation for the Accreditation of Cell Therapy (FACT) and the Joint Accreditation Committee of ISCT\u2010Europe and EBMT (JACIE).http:\/\/www.jacie.org"},{"key":"e_1_2_6_15_2","unstructured":"World Marrow Donor Association (WMDA) Standards March 2005 available at:http:\/\/www.worldmarrow.org"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700943"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1423-0410.2010.01329.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1423-0410.2010.01329.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T15:40:44Z","timestamp":1692546044000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1423-0410.2010.01329.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,14]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1423-0410.2010.01329.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1423-0410.2010.01329.x","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,14]]}}}